MedTrace Logo

Discharge Counseling and Medication Therapy Management (MTM) Services After Discharge for Heart Failure Patients

NCT01822171 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2013-05-22

No results posted yet for this study

Summary

Readmission to a hospital shortly after discharge is a common and costly problem. In the United States patients with a diagnosis of heart failure currently experience an elevated 30 day readmission rate of approximately 20%. By providing patients with medication related counseling at discharge by a pharmacist, home medications at discharge, and seeing the patient again in a pharmacist-run Medication Therapy Management (MTM) clinic 7 days after discharge, the study anticipates achieving its primary goal of showing a reduction in the readmission rate. Secondary goals are: 1) to determine patients understanding of the medication they are taking, 2) to evaluate satisfaction with the comprehensive discharge counseling service, and 3) determine the number of interventions made and benefit of the MTM clinic.

Conditions

Interventions

OTHER

Discharge medication counseling from a pharmacist

Patient will be educated about proper dosing instructions, potential side effects, and when to recontact the treating physician office.

OTHER

Home medication if needed

Patient will be provided with medication to take home, when needed.

OTHER

Follow-up visit at Medication Therapy Management clinic

This comprehensive Medication Therapy Management clinic follow-up visit is scheduled for 7 days post hospital discharge. The approximately 1 hour visit is scheduled with a pharmacist to review current drug therapy and make recommendations, if needed, to improve medication utilization.

Sponsors & Collaborators

  • Providence Health & Services

    lead OTHER

Principal Investigators

  • Laura Hoekstra, Pharm.D. · Providence St. Peter Hospital

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01822171 on ClinicalTrials.gov